GTB will continue to provide a professional, authoritative, and historical perspective, partnering with global brands to ...

Cognizant margins hold near 11% despite gross pressure from wage inflation and competition. Read here for a detailed analysis ...

The complex fluid–structure interaction underlying blood flow through vessels has proved challenging to analyze both ...

Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion ...

Concluding an intensive training program aimed at nurturing the skills of university students in the fields of economy and ...

Laughing Water Capital reported a 3.9% annual return, emphasizing fundamental growth in core holdings despite a market ...

The Board of Trustees will learn about the Teaching and Assessing Experiential Learning Certification, as well as the OHIO ...

The political deliberations and deal-making within the marbled halls of the Idaho Capitol may seem far removed from everyday ...

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...

Intellia's current market position is defined by the tension between its long-term technological promise and immediate safety concerns. The stock came under sustained pressure starting in late 2025 ...

BGC Group, Inc. , today announced that it has updated its outlook for the quarter ending December 31, 2025. Updated Outlook BGC reaffirmed its previously stated outlook ranges for revenue and pre-tax ...